Addex Therapeutics Ltd
ADXN
$7.10
-$0.2022-2.77%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 630.00K | 938.90K | 1.51M | 1.79M | 2.23M |
| Total Other Revenue | 41.10K | 37.60K | 38.80K | 38.40K | 10.80K |
| Total Revenue | 671.30K | 976.50K | 1.55M | 1.83M | 2.24M |
| Cost of Revenue | 2.64M | 2.96M | 2.91M | 2.90M | 3.59M |
| Gross Profit | -1.97M | -1.98M | -1.35M | -1.08M | -1.35M |
| SG&A Expenses | 3.68M | 3.79M | 3.87M | 3.64M | 3.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.32M | 6.75M | 6.77M | 6.54M | 7.56M |
| Operating Income | -5.64M | -5.77M | -5.22M | -4.72M | -5.32M |
| Income Before Tax | -7.44M | -6.48M | -5.45M | -5.01M | -5.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.44 | -6.48 | -5.45 | -5.01 | -5.58 |
| Earnings from Discontinued Operations | 13.16M | 11.00M | -7.24M | -6.76M | -6.76M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.72M | 4.52M | -12.70M | -11.77M | -12.33M |
| EBIT | -5.64M | -5.77M | -5.22M | -4.72M | -5.32M |
| EBITDA | -5.45M | -5.64M | -5.20M | -4.70M | -5.27M |
| EPS Basic | 0.05 | 0.03 | -0.15 | -0.16 | -0.19 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.04 | -0.04 | -0.06 |
| EPS Diluted | 0.05 | 0.03 | -0.16 | -0.16 | -0.19 |
| Normalized Diluted EPS | -0.05 | -0.04 | -0.04 | -0.04 | -0.06 |
| Average Basic Shares Outstanding | 380.47M | 359.45M | 333.33M | 297.05M | 267.74M |
| Average Diluted Shares Outstanding | 450.16M | 429.14M | 333.33M | 297.05M | 267.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
